Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.
Por:
Madero Velázquez L, Muñoz Pérez R, Rodríguez A, Bernal L, Orts B, Sempere L and Gutiérrez Casbas A
Publicada:
1 ene 2022
Ahead of Print:
2 feb 2022
Resumen:
Carboxymaltose iron (Ferinject®) is a formulation for intravenous (iv) administration, used for the treatment of iron deficiency anemia and/or iron deficiency when oral administration of iron is not effective or due to intolerance. Its safety profile is excellent with few, but not nonexistent, side effects. Hypophosphatemia has been described as one of them. It is usually mild, transient and asymptomatic. However, in some cases it may be accompanied by nausea, asthenia, in addition to muscular and neurological symptoms and hematological alterations. It is, therefore, a potentially serious adverse effect whose prevalence is unknown and which requires high clinical suspicion to be detected.
Filiaciones:
:
Aparato Digestivo, Hospital General Universitario de Alicante, España
:
Aparato Digestivo, Hospital General Universitario de Alicante
Rodríguez A:
Aparato Digestivo, Hospital General Universitario de Alicante
Bernal L:
Aparato Digestivo, Hospital General Universitario de Alicante
:
Farmacia, Hospital General Universitario de Alicante
:
Aparato Digestivo, Hospital General Universitario de Alicante
:
Aparato Digestivo, Hospital General Universitario de Alicante
gold
|